DDInter1610 DDInter484
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dasatinib
Rivastigmine {u} (Compound) upregulates {v} (Gene) ST6GALNAC2
ST6GALNAC2 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Rivastigmine {u} (Compound) downregulates {v} (Gene) IFRD2
IFRD2 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Rivastigmine {u} (Compound) upregulates {v} (Gene) MELK
MELK {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Dasatinib
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) FMO3
FMO3 {u} (Gene) is bound by {v} (Compound) Dasatinib
Rivastigmine {u} (Compound) upregulates {v} (Gene) ST6GALNAC2
ST6GALNAC2 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Dasatinib
Rivastigmine {u} (Compound) downregulates {v} (Gene) IFRD2
IFRD2 {u} (Gene) is regulated by {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Dasatinib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dasatinib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Fluid retention
Fluid retention {u} (Side Effect) is caused by {v} (Compound) Granisetron
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Rivastigmine (Compound) upregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is upregulated by Dasatinib (Compound)
Rivastigmine (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by Dasatinib (Compound)
Rivastigmine (Compound) upregulates MELK (Gene) and MELK (Gene) is downregulated by Dasatinib (Compound)
Rivastigmine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with FMO3 (Gene) and FMO3 (Gene) is bound by Dasatinib (Compound)
Rivastigmine (Compound) upregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Dasatinib (Compound)
Rivastigmine (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is regulated by ABCG2 (Gene) and ABCG2 (Gene) is bound by Dasatinib (Compound)
Rivastigmine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Rivastigmine (Compound) causes Fluid retention (Side Effect) and Fluid retention (Side Effect) is caused by Granisetron (Compound) and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib